autologous blood and marrow transplantation - Blog Science ...

Ball et al. 21
CD15) and AML-2-23 (anti-CD14) bind to leukemia cells from >95% of AML
patients. 19,20
These mAbs are cytotoxic to cells in the presence of complement (C)
2 1
and thus can lyse leukemia cells from almost all patients with AML.
From 25 August 1984 until 10 February 1997, 140 purged autotransplants were
performed on 138 patients who were in CR or first relapse at the time of transplant.
Sixty of these patients were described in a previous report. 17
We now report on the
long-term results of these phase II studies.
PATIENTS AND METHODS
Patients
Patients 2 months were eligible for this protocol. At the time
of bone marrow harvest, remission had to be documented by bone marrow aspirate
and biopsy. Patients underwent harvest in first, second, or third CR. Transplants
were performed in CR1, CR2, CR3, or first relapse (Rl). Leukemia blast cells
obtained at diagnosis or at relapse were required to express the antigens reactive
with PM-81 and/or AML-2-23 on >20% of cells. The study was approved by the
Institutional Review Board of the respective institutions, and a signed informed
consent was obtained from each patient before study entry.
One hundred thirty-eight AML patients (with two patients undergoing
retransplantation) ranging in age from 2 to 57 years in CR or first relapse were
transplanted between 25 August 1984 and 10 February 1997 (Table 1). All but
11 patients had de novo AML at the time of initial diagnosis. Eleven patients
had a myelodysplastic syndrome (MDS) before the diagnosis of AML. Twenty
patients were treated on CALGB protocols 8882 or 8781. Four patients were
transplanted at the Scripps Clinic (La Jolla, CA) and Children's Hospital (San
Diego, CA), 59 at the Dartmouth-Hitchcock Medical Center (DHMC, Hanover,
NH), 14 at Bowman-Gray School of Medicine (Winston-Salem, NC), four at the
Medical Center of Delaware (Newark, DE), six at the University of Iowa
Hospitals, 23 at the University of Pittsburgh, four at the University of Alabama,
two at Children's Hospital of Pittsburgh, one at the University of Colorado, four
at Miami Children's Hospital, four at Shands Hospital (Gainesville, FL), 10 at
Stanford University Medical Center, and one at the Harris Methodist Hospital
(Ft. Worth, TX).
The FAB subclasses of the cases were as follows: M1/M2, 61; M3, 16; M4/M5,
51; M6/M7, three; biphenotypic, one; unknown, seven. Cytogenetic analysis on the
leukemia cells at presentation were available from the records of 103 patients.
The median time between the current remission or relapse and autoBMT
(n=137) was 53 days (range 3-420). The median time between the current